Chronic Gout Insights and Trends

• Chronic gout is one of the most prevalent inflammatory arthritic disorders globally, with increasing incidence driven by rising rates of obesity, metabolic syndrome, hypertension, diabetes, and chronic kidney disease (CKD).
• In the United States, gout affects approximately 9–10 million adults (~4% of the adult population), making it a significant contributor to musculoskeletal morbidity and healthcare burden.
• The prevalence of gout is substantially higher in men and older adults, with epidemiological studies showing increasing disease burden with advancing age due to reduced renal uric acid clearance and accumulation of comorbidities.
• A considerable proportion of patients remain inadequately controlled despite urate-lowering therapy, and approximately 2–5% of gout patients may progress to chronic refractory gout (CRG), characterized by persistent hyperuricemia, recurrent flares, tophi formation, and progressive joint damage.

Chronic Gout Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Chronic Gout: ~2,413,400
• 2036 Projected Diagnosed Prevalent Cases of Chronic Gout: ~XXX
• Chronic Gout  Growth Rate (2026–2036): ~0.5% CAGR

DelveInsight's ‘Chronic Gout Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Chronic Gout, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Chronic Gout Understanding and Diagnosis Algorithm

Chronic Gout Overview and Diagnosis

Chronic gout is a chronic inflammatory arthritic disorder caused by prolonged hyperuricemia and deposition of monosodium urate (MSU) crystals in joints and surrounding tissues. The disease commonly presents with recurrent gout flares, persistent joint pain, swelling, stiffness, and tophi formation, particularly in the lower extremities such as the great toe, ankles, knees, and feet. Over time, uncontrolled disease may lead to chronic joint damage, deformities, reduced mobility, renal stones, and CKD. Chronic refractory gout (CRG) represents a severe form of gout in which symptoms and serum urate levels remain inadequately controlled despite standard urate-lowering therapies.

Further details are provided in the report.

Chronic Gout Diagnosis

Diagnosis of chronic gout is primarily based on clinical evaluation, serum uric acid assessment, and identification of MSU crystals in synovial fluid or tophi aspirates using polarized light microscopy, which remains the gold standard for diagnosis. Imaging techniques such as X-ray, ultrasound, and Dual-Energy CT (DECT) are increasingly used to detect urate crystal deposits, tophi burden, and structural joint damage. Additional laboratory investigations, including renal function tests and inflammatory markers, help assess disease severity, associated comorbidities, and treatment response.

Further details are provided in the report.

Chronic Gout Epidemiology

Key Findings from Chronic Gout Epidemiological Analysis and Forecast 

• In 2025, over ~10.5 million individuals in the US were diagnosed with gout, highlighting a significant burden of this chronic inflammatory condition across the population.
• In 2025, Italy reported the lowest number of diagnosed prevalent cases of chronic gout among major countries.
• Among EU4 and the UK, Germany, accounted nearly ~171,000 cases diagnosed prevalent cases of chronic gout in 2025, while France accounted for more than ~73,000 cases. The cases are expected to rise across EU4 and the UK.
• As per secondary analysis, the prevalence of gout is greater than 1% in most developed countries, including the US (3.9%), Germany (1.4%), and the UK (2.5%).
• The prevalence of gout in Italy increased from 0.67% in 2005 to 0.9% in 2009. In adults older than 20 years, the male-to-female ratio ranged from 2.5 (>90 years) to 11 (35–39 years), demonstrating a significantly higher disease burden among males.

Scope of the Report

• The report covers a segment of a descriptive overview of chronic gout, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Chronic Gout Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of chronic gout? What will be the growth opportunities across the 7MM concerning the patient population with chronic gout?
• What is the historical and forecasted chronic gout patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.